Apomorphine Revived: Fortified, Prolonged, and Improved Therapeutical Effect

References

• Andén N. E., et al. Evidence for dopamine receptor stimulation by apomorphine. J. Pharm. Pharmacol. 1967; 19: 627–629
   PubMed Web of Science ®Google Scholar
• Beil H., Trojan A. Erste Ergebnisse der ambulanten Apomorphinbehandlung bei 123 Suchtkranken. Therapicwoche 1975; 25(16)2195
   Google Scholar
• Benkert O., et al. Effect of l-dopa on sexually impotent patients. Psychopharmucologia (Berlin) 1972; 23: 91–95
   PubMedGoogle Scholar
• Benkert O. Studies on pituitary and releasing hormones in depression and sexual impotence. Prog. Brain Res. 1975; 42: 25–36
   PubMedGoogle Scholar
• Benkert O., et al. Sexual impotence—A double blind study of LHRH Nasal spray versus placebo. Neuropsychology
   Google Scholar
• Benkert O., Beckmann H. Disulfiram effect on depression and paranoid score. Pharmakopsychialrie. Neuropsychopharmakologie 1974; 4(2)94–99
   Google Scholar
• Buus S., et al. Apomorphin anvendt i rus. og abstinensbehandlingen. Ugeskr. Laeg. 1974; 136(32)1808–1813
   PubMedGoogle Scholar
• Carlsson A., et al. Suppression by dopamine-agonists of the ethanol-induced stimulation of locomotor activity and brain dopamine synthesis. Naunyn-Schmieclehergs Arch. Pharmacol 1974; 283: 117–128
   PubMed Web of Science ®Google Scholar
• Castaigne P., et al. Clinical experimentation with apomorphine in Parkinsons disease. Res. Commun. Chem. Pathol. Pharmacol. 1972; 2(2)154–158
   Google Scholar
• Cotzias G. C. Metabolic modification of some neurologic disorders. J. Am. Med. Assoc. November 17, 1969; 210(7)1255–4262
   Web of Science ®Google Scholar
• Cotzias G. C., et al. Apomorphine and Parkinsonism. Trans. Am. Neurol. Assoc. 1973; 97: 156–159
   Google Scholar
• Dent J. Y. Apomorphine in the treatment of anxiety states, with special reference to alcoholism. Br. J. Inebr. 1934; 32(2)65–88
   Google Scholar
• Dent J. Y. Apomorphine in the treatment of addiction to other drugs. Br. J. Addict. 1953; 50(1)43–46
   Google Scholar
• Dittert L. W., Disanto A. R. The bioavailability of drug products. J. Am. Pharm. Assoc. 1973; NS13(8)421–432
   Google Scholar
• Douglas C. J. Alcoholism. N.Y. Med. J. 1899; 70: 626–628
   Google Scholar
• Douglas C. J. Delirium tremens. N.Y. Med. J. 1900; 72: 852
   Google Scholar
• Düby S. E., et al. Injected apomorphine and orally administered levodopa in Parkinsonism. Arch. Neurol. 1972; 27: 474–480
   PubMedGoogle Scholar
• Feldmann H. Contribution a la Therapeutique Biologique de l'Alcoolism Chronique. Le Traitement Par L'Apomorphine. Etude de 150 cas. Thesis, University of Geneva. 1950
   Google Scholar
• Feldmann H. The ambulatory treatment of alcoholic addiction. A study of 250 cases. Br. J. Addict. 1959; 55(2)121–127
   Google Scholar
• Gottesfeld B. H., et al. Psychiatric implications of the treatment of alcoholism with tetraethylthiuram disulfide. Q. J. Stud. Alcohol 1951; 12(2)184–205
   PubMedGoogle Scholar
• Gylding-Sabroe J. P., Hattel T. Metoclopramide. A new quick-acting antiemetic. Nord. Med. 1969; 81: 141–142
   PubMedGoogle Scholar
• Halvorsen K. A.L. Nuevo tratamiento del alcoholismo. Dia Med. 1949; 32: 1256
   Google Scholar
• Halvorsen K. A.L. Fifth International Institute on the Prevention and Treatment of Drug Dependence, CopenhagenDenmark, July, 8–121974, Apomorphine in the Treatment of Drug Dependence. Addendum I. Goteborg, October 1974. Addendum II
   Google Scholar
• Heath R. G., et al. Behavioral and metabolic changes associated with administration of tetraethylthiuram disulphide (Antabus). Dis. Nerv. Syst. 1965; 26: 99–105
   PubMedGoogle Scholar
• Klein R. L., et al. Antiemetic effect of metoclopramide. Evaluation in humans. Anesth. Analg. 1968; 47: 259–264
   PubMed Web of Science ®Google Scholar
• Lal S., et al. Effect of apomorphine on human growth hormone secretion. Lancet September 23, 1972; 2: 661
   PubMed Web of Science ®Google Scholar
• Martensen-Larsen O. Treatment of alcoholism with a sensitizing drug. Lancet 1948; 255: 1004–1005
   Google Scholar
• Martensen-Larsen O. Psychotic phenomena provoked by tetraethylthiuram disulfide. Q. J. Stud. Alcohol 1951; 12: 206–216
   PubMedGoogle Scholar
• Martensen-Larsen O. Five years experience with disulfiram in the treatment of alcoholics. Q. J. Stud. Alcohol 1953; 14: 406–418
   PubMedGoogle Scholar
• Martensen-Larsen O. Apomorphine and disulfiram in the treatment of alcoholism. Twentieth International Institute on the Prevention and Treatment of Alcoholism., ManchesterEngland, June, 24–281974
   Google Scholar
• Martensen-Larsen O., Glud E. The use of disulfiram, apomorphine and other drugs in the treatment of acute intoxications. Twenty-sixth International Congress on Alcohol and Alcoholism., Stockholm, 1960
   Google Scholar
• Mathiesen A., Wright C. R. Apomorphine. Proc. R. Soc. Med. 1869; 17: 455, 18: 88, 1869
   Google Scholar
• Moynihan N. H. The treatment of alcoholism in general practise. Gen. Practioners Forum 1965; 195: 223
   Google Scholar
• Oswald I. Psychoactive drugs and sleep. Withdrawal rebound phenomena. Triangle 1971; 10(3)99–104
   PubMedGoogle Scholar
• Scheel-Krüger J. The Treatment of Multiple Drug Dependence and Alcoholism with Apomorphinenew ed., H. Beil, Hamburg 1976; 93–121
   Google Scholar
• Schlatter E. K. E., et al. Treatment of alcoholism with Dent's oral apomorphine method. Q. J. Stud. Alcohol 1972; 33: 430–436
   PubMedGoogle Scholar
• Schwab R., et al. Apomorphine in Parkinson's disease. Trans. Am. Neurol. Assoc. 1951; 76: 251
   Google Scholar
• Strian F., et al. Tremor inhibition in Parkinson syndrome after apomorphine, under l-dopa and decarboxylase inhibitor basic therapy. Pharmakopsychiatr. Neuro-Psychopharmakol. July, 1972; 5(4)198–205
   Google Scholar
• Ziegler B., Schneider E. Behandlung des Entzyndungs Syndrom mit Apomorphine. Arzneim. Forsch. 1974; 24(8)
   Google Scholar